MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors

Last updated: January 17, 2025
Sponsor: Rutgers, The State University of New Jersey
Overall Status: Active - Recruiting

Phase

N/A

Condition

Melanoma

Treatment

Educational webpage on SSE

Assess implementation outcomes

MySmartSkin enhancement

Clinical Study ID

NCT05373823
CINJ132202
R01CA264548
  • Ages > 18
  • All Genders

Study Summary

This project, mySmartSkin (MSS), includes an innovative Type 1 hybrid effectiveness-implementation trial designed to enhance the effects of MSS and simultaneously assess key implementation outcomes (e.g., cost, adoption) as well as contextual factors important for scale-up in community and health care settings where melanoma survivors receive follow-up care. A type 1 hybrid effectiveness-implementation design allows us to engage multilevel stakeholders throughout this process, evaluate the effectiveness of the enhanced MSS, and identify critical factors for wide-scale implementation. Aim 1 will focus on enhancing the previous version of MSS by collaborating with multi-level stakeholders in qualitative interviews and usability testing. Aim 2 will evaluate the effects of enhanced MSS on thorough skin-self examinations (SSE) in a randomized-control trial (RCT) and examine its impact on the diagnosis of new/recurrent melanomas. Aim 3 will focus on assessing selected implementation outcomes and identify factors relevant to future scale-up for widespread dissemination and implementation.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of primary pathologic stage 0-III cutaneous malignant melanoma

  • Three months to five years post-surgery

  • No current evidence of cancer

  • Not adherent to thorough SSE (i.e., did not check entire body at least once duringthe past three months)

  • ≥ 18 years old

  • Internet access

  • Able to speak/read English

  • Able to provide informed consent

Exclusion

Exclusion Criteria:

  • Children

Study Design

Total Participants: 385
Treatment Group(s): 5
Primary Treatment: Educational webpage on SSE
Phase:
Study Start date:
March 06, 2023
Estimated Completion Date:
March 31, 2027

Study Description

This is a type one hybrid effectiveness-implementation study consisting of three aims. Aim one (Months 1-15) focuses on MSS enhancement using stakeholder collaboration. Aim two (Months 16-60) involves the longitudinal randomized control trial (RCT) comparing behavioral outcomes and effectiveness of enhanced MSS versus an educational webpage. Aim three (Months 16-60) will assess implementation outcomes and identify contextual factors to facilitate scale-up for future dissemination and implementation.

Connect with a study center

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey 08901
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.